Agmatine
Endogenous decarboxylated arginine metabolite sold mainly as agmatine sulfate. Proposed neuromodulatory and pain-related effects are supported mostly by mechanistic and animal literature; human oral exposure and effectiveness remain poorly characterized.
Pharmacokinetic model
A route-level PK model for agmatine is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Amino Acid Metabolite
- Suggested cadence
- once daily
Research behind this entry
-
Neuroprotection by agmatine: Possible involvement of the gut microbiome?
Narrative review discusses proposed neuroprotective and gut-microbiome mechanisms. It synthesizes predominantly preclinical evidence and does not establish human oral pharmacokinetics or clinical efficacy.
-
Regulatory mechanisms underlying agmatine homeostasis in humans
Portal and hepatic venous sampling in people with cirrhosis showed concentration-dependent hepatic handling of endogenous agmatine. The study was not oral supplementation PK in healthy people and cannot be converted…
-
Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial.
This citation reports a human clinical study involving Agmatine. It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.
3 published studies referenced in the app, each with a plain-language summary.